Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly

European Journal of Endocrinology

Volumn 157, Issue 5, 2007, Pages 579-587

  Colao, Annamaria ^a   Pivonello, Rosario ^a   Auriemma, Renata S ^a   Galdiero, Mariano ^a   Savastano, Silvia ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM CHELATE; GLUCOSE; GROWTH HORMONE; INSULIN; METFORMIN; OCTREOTIDE; SOMATOMEDIN C;

ABDOMINAL DISCOMFORT; ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLATULENCE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HAIR LOSS; HUMAN; HYPOPHYSIS ADENOMA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEATORRHEA; TUMOR VOLUME;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PROSPECTIVE STUDIES;

EID: 36549040940     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0383     Document Type: Article

References (33)

1. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006 355 2558-2573.
2. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473.
3. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L & Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism 2006 91 1397-1403.
4. Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1856-1863.
5. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance M-L, Rhew D, Kleinberg D & Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4405-4410.
6. Colao A, Pivonello R, Auriernma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S & Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2112-2118.
7. Turner HE, Vadivale A, Keenan J & Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clinical Endocrinology 1999 51 275-280.
8. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D & Pedroncelli AM. Four-year treatment with octreotide-LAR in 110 acromegalic patients: the predictive value of short-term results by ROC analysis. Journal of Clinical Endocrinology and Metabolism 2003 88 3090-3098.
9. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I & Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism 2001 86 2779-2786.
10. Colao A & Lombardi G. Growth hormone and prolactin excess. Lancet 1998 352 1455-1461.
11. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
12. Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M & Lombardi G. First-line octreotide, LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clinical Endocrinology 2006 64 342-351.
13. American Diabetes Association Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2006 29 S43-S48.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
15. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M & Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1996 81 2356-2362.
16. Sheppard MC. Primary medical therapy for acromegaly. Clinical Endocrinology 2003 58 387-399.
17. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocrine Reviews 2004 25 102-152.
18. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM & Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 1613-1617.
19. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman VH, Vükari J & Voutilainen E. A nationwide survey of mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4081-4086.
20. Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E & ALICE Study Group. First-line therapy of acromegaly: a statement of the ALICE (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. Journal of Clinical Investigation 2006 29 1017-1020.
21. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron F, Charbonnel B, Cortet C, Delemer B, Escobar-Jimenez F, Foubert L, Gaztambide S, Jockcnhoovel F, Kuhn JM, Leclerc J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassdas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F & Webb SM. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clinical Endocrinology 2000 53 577-586.
22. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P. Lamberts SW, Marbach P, Orskov H, Pagani G, Sheppard M & Simionesan L. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996 45 67-71.
23. Ayuk J, Stewart SE, Stewart PM & Shepparld MC. Long-term safety and efficacy of depot long-acting somatostatin analogues for the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 2002 87 4142-4146.
24. Herman-Bonert VS, Zib K, Scarlett JA & Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism 2000 85 2958-2961.
25. Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM & Trainer PJ. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. European Journal of Endocrinology 2001 145 451-458.
26. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ & Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance, European Journal of Endocrinology 2006 154 467-477.
27. Schreiber I, Buchfelder M, Droste M, Forssmarm K, Mann K, Saller B, Strasburger CJ & the German Pegvisomant Investigators. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study, European Journal of Endocrinology 2007 156 75-82.
28. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G & Giordano G. Clinical results of long-term slow-release lanreotide treatment of acromegaly. European Journalof Clinical Investigation 1997 27 277-284.
29. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V & Tamburrano G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clinical Endocrinology 2003 59 492-499.
30. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ & Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2005 90 5684-5691.
31. Freda PU. Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2002 87 3013-3018.
32. Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A & Lombardi G. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. European Journal of Endocrinology 2007 156 S57-S63.
33. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646.